Context Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the issuance of non-qualified stock option awards as part of its compensation strategy. On May 12, 2025, the company granted options to purchase a total of 160,000 shares of common stock to two newly hired employees. These options, issued outside of the 2021 Long-Term Performance Incentive Plan, are aligned with Nasdaq Listing Rule 5635(c)(4). The exercise prices are set at $0.839 and $0.78 per share, corresponding to the closing prices on the respective grant dates of May 5 and May 12, 2025. The stock options come with a 10-year term and a four-year vesting schedule, beginning with one-fourth of the shares vesting after the first year, followed by monthly installments, contingent on the employees' continued service with the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。